MWNA
PTGX icon

Marshall Wace North America’s Protagonist Therapeutics PTGX Stock Holding History

Marshall Wace North America’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-44,385
Closed -$1.15M – 1709
2021
Q1 		$1.15M Sell
44,385
-16,663
-27% -$422K ﹤0.01% 998
2020
Q4 		$1.23M Buy
+61,048
New +$1.31M 0.01% 889

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace North America's PTGX Position: Q2 2021 in Review

Marshall Wace North America sold out of Protagonist Therapeutics (PTGX) in Q2 2021, closing a stake of 44,385 shares — an estimated $1.15M sold.

Marshall Wace North America first reported a position in PTGX in Q4 2020 and held it in 2 quarters. The position peaked at $1.23M in Q4 2020. 138 funds tracked by Wall St. Rank hold PTGX as of Q2 2021.

  • Marshall Wace North America reported no remaining Protagonist Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 44,385 Protagonist Therapeutics shares in Q2 2021, an estimated $1.15M.
  • Marshall Wace North America first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 2 quarters.
  • Marshall Wace North America's Protagonist Therapeutics position peaked at $1.23M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.